<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>27(1)</volume><submitter>Paramonova M</submitter><pubmed_abstract>Graphical abstract  The title compounds were prepared from 1-[5-(4-bromophenoxy) pentyl]uracil by the introduction of N-arylacetamide moiety at the 3-position, the better approach involving the use of N-aryl-2-chloroacetamides as the reactants. Antiviral activity of the obtained compounds was estimated.</pubmed_abstract><journal>Mendeleev Communications</journal><pagination>85-87</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7148871</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Novel 1-[5-(4-bromophenoxy)pentyl]-3-(2-arylamino- 2-oxoethyl)uracils and their antiviral properties</pubmed_title><pmcid>PMC7148871</pmcid><pubmed_authors>Paramonova M</pubmed_authors><pubmed_authors>Khandazhinskaya A</pubmed_authors><pubmed_authors>Seley-Radtke K</pubmed_authors><pubmed_authors>Novikov M</pubmed_authors></additional><is_claimable>false</is_claimable><name>Novel 1-[5-(4-bromophenoxy)pentyl]-3-(2-arylamino- 2-oxoethyl)uracils and their antiviral properties</name><description>Graphical abstract  The title compounds were prepared from 1-[5-(4-bromophenoxy) pentyl]uracil by the introduction of N-arylacetamide moiety at the 3-position, the better approach involving the use of N-aryl-2-chloroacetamides as the reactants. Antiviral activity of the obtained compounds was estimated.</description><dates><release>2017-01-01T00:00:00Z</release><publication>2017 Jan</publication><modification>2025-04-04T03:42:33.547Z</modification><creation>2020-05-22T17:00:47Z</creation></dates><accession>S-EPMC7148871</accession><cross_references/></HashMap>